|
|
|
|
|
09.07.26 - 20:30
|
Eli Lilly′s $400 Billion Surge Is Reshaping Big Pharma (24/7 Wall St.)
|
|
|
Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY) has added over the past year, with shares climbing from $773.86 on July 2, 2025 to $1,213.91 on July 2, 2026, a 56.86% gain that has pushed the drugmaker's market capitalization to $1.063 trillion. No other Big Pharma name has expanded its footprint ... Eli Lilly's $400 Billion Surge Is Reshaping Big Pharma...
|
|
|
|
|
|
|
09.07.26 - 12:15
|
Novo Nordisk-Aktie: Singapur-News? First-Mover-Vorteil bleibt wichtiger! (Sharedeals)
|
|
|
Novo Nordisk befindet sich in 2026 in einem Schicksalsjahr: Es gilt bei der aufkommenden Konkurrenz um Eli Lilly und kleineren Wettbewerbern zu zeigen, dass man einerseits führend im Diabetesmarkt bleibt. Andererseits muss der dänische Pharmaspezialist beweisen, dass man auch im Adipositas-Segment nach wie vor eine Rolle spielt und vom Wachstum profitieren kann. Nun gibt es […]
The post Novo Nordisk-Aktie: Singapur-News? First-Mover-Vorteil bleibt wichtiger! first appeared on sharedeals.de....
|
|
|
09.07.26 - 10:03
|
Alchemab Therapeutics Announces Largest Ever Life Sciences Investment From British Business Bank to Advance AI-Enabled Clinical Pipeline of Next Generation Human-Derived Antibodies (Business Wire)
|
|
|
CAMBRIDGE, England--(BUSINESS WIRE)--Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34 million) investment from the British Business Bank – the Bank's largest investment in a life sciences company to date. The funding will enable the company to build its clinical pipeline and grow its unique proprietary antibody dataset to more than a billion sequences.Alchemab is discovering and developing first-in-class drugs through its Resiliome™ platform, which uses complex AI derived algorithms to identify naturally occurring antibodies present in humans with unusual resilience to a range of hard-to-treat diseases.This investment builds on the success of the company's first asset, ATLX-1282 – a first-in-class antibody therapeutic in clinical development for amyotrophic lateral sclerosis (ALS) which was licensed to Eli Lilly and has provided robust validation of the potential of the Resiliome approach.The additional funding brings Alchemab's total S...
|
|
|
|
|
|
|
08.07.26 - 18:06
|
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity (24/7 Wall St.)
|
|
|
The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow process measured in years and billions of dollars, is increasingly becoming a data-driven competition. Companies that combine proprietary medical data with AI tools may gain an advantage similar to what technology companies achieved during the ... Wall Street Is Betting on Eli Lilly's GLP-1 Portfolio — It's Missing the $1 Trillion Opportunity...
|
|
|
|
|
|
|
08.07.26 - 14:48
|
This $1,200 Stock Could Be the Next Massive Stock Split Opportunity (24/7 Wall St.)
|
|
|
The Number $8.662 billion. That is what Mounjaro alone generated for Eli Lilly (NYSE:LLY) in the first quarter of 2026, a single product, a single quarter, up 125% year over year. The figure was disclosed in Lilly's Q1 2026 earnings release on April 30, 2026, an actual reported figure. This key growth driver is what ... This $1,200 Stock Could Be the Next Massive Stock Split Opportunity...
|
|
|
|
|
|
|
|
|
08.07.26 - 08:39
|
Megatrend Folger: Eli Lilly sprengt die Billionen-Marke (Der Aktionaer)
|
|
|
Eli Lilly marschiert weiter an der Spitze des globalen Gesundheitssektors. Die Aktie des US-Pharmagiganten kletterte am Dienstag auf ein neues Allzeithoch und lässt damit die Marke von einer Billion als Marktkapitalisierung klar hinter sich. Rückenwind liefern optimistische Analystenkommentare und der anhaltende Erfolg der GLP-1-Präparate Mounjaro und Zepbound....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
